Hints and tips:
Related Special Reports
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...It already made its diagnostics products in the country but had “limited manufacturing for pharma”, he added....
...He added that the underlying operative problems in the pharma and crop science businesses needed to be addressed without undue job cuts....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...The company also faces the expiration of key patents in its pharma division and last year aborted a late-stage trial of its most hopeful new drugs....
The Swiss pharma group needs to settle investor jitters with its latest acquisition
...Chief executive Bill Anderson, who joined last year after heading the pharma unit of Swiss rival Roche, said the decision “was not taken lightly” and had “considered investor input.”...
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...This raises funds for Schott AG’s green transition and gives Schott Pharma a chance to tap the capital markets if opportunities arise. The size of the offer is undecided....
...Manns said asundexian was the most promising drug in Bayer’s pharma pipeline. “Without it, the pharma unit is left without sustainable growth.”...
...The new chief executive, who has been in the job since the summer and previously ran Roche’s pharma division, disagreed that Bayer’s pharma unit was too small to keep up with larger rivals....
...Last month he blasted Bayer’s performance as “unacceptable” and stressed that “all options” were on the table, including splitting the pharma unit from the crop science division....
...It’s a spoiler for Wall Street and Big Ag, and Big Tech, and Big Telecom, and Big Pharma, and the corporate- owned media and all the corrupt politicians and corporations.”...
...Its — untested — argument is that Amgen could use rebates on its blockbusters to encourage insurers and pharmacy benefit managers to favour Horizon’s drugs....
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
...Yet the German conglomerate is making rapid moves in its pharma division....
...You could imagine tweaking the chemistry to address other targets,” said Michael Lobritz, global head of infectious diseases at Roche Pharma Research & Early Development....
...Horizon Pharmaceuticals was down more than 17 per cent before the opening bell after Bloomberg reported late on Monday that the Federal Trade Commission was expected to block Amgen’s $28.3bn acquisition...
...People with knowledge of Khan’s plans said he viewed the US market with a seven-year time horizon....
...Big Pharma has always bought out small drug developers to restock its pipelines. Some emerging health science companies aspire to be the next Amgen, which has a market capitalisation of $120bn....
...But pressure is mounting on pharma companies to switch to synthetic substances as populations decline for horseshoe crabs and seabirds that eat the creatures’ eggs....
...Amgen and Horizon indicated they would try to complete the deal by fighting the FTC in court....
...Shares in large pharma companies that are also developing anti-TIGITs rose....
...Third, comprehensive regulation is on the horizon. [ . . . ] We perceive regulation as a net positive for the industry as it will: (i) increase adoption as a clearer regulatory framework should drive more...
...Last month the Federal Trade Commission caused shockwaves when it sued to block Amgen’s takeover of Horizon Therapeutics — a $28bn deal announced in December that kick-started the nascent M&A recovery....
International Edition